×
About 945 results

ALLMedicine™ Guillain-barre Syndrome Center

Research & Reviews  293 results

Cerebrospinal Fluid Analysis
http://emedicine.medscape.com/article/2093316-overview

Jun 16th, 2022 - Reference Range Characteristics of normal spinal fluid are below: [1, 2, 3, 4] Total volume: 150 mL Color: Colorless, clear, like water Pressure: < 20 cm H 2O Osmolarity at 37°C: 281 mOsm/L Specific gravity: 1.006 to 1.008 Acid-base balance: pH: 7...

Cerebrospinal Fluid Analysis
https://emedicine.medscape.com/article/2093316-overview

Jun 16th, 2022 - Reference Range Characteristics of normal spinal fluid are below: [1, 2, 3, 4] Total volume: 150 mL Color: Colorless, clear, like water Pressure: < 20 cm H 2O Osmolarity at 37°C: 281 mOsm/L Specific gravity: 1.006 to 1.008 Acid-base balance: pH: 7...

Cerebrospinal Fluid Analysis
https://emedicine.medscape.com/article/2093316-print

Jun 16th, 2022 - Characteristics of normal spinal fluid are below:[1, 2, 3, 4] Total volume: 150 mL Color: Colorless, clear, like water Pressure: < 20 cm H 2O Osmolarity at 37°C: 281 mOsm/L Specific gravity: 1.006 to 1.008 Acid-base balance: pH: 7.28-7.32 Pco2: 47...

Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: ...
https://doi.org/10.1016/j.annonc.2022.05.519
Annals of Oncology : Official Journal of the European Soc... Maio M, Ascierto PA et. al.

Jun 10th, 2022 - Pembrolizumab demonstrated durable antitumor activity in 233 patients with previously treated advanced microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors in the phase 2 multicohort KEYNOTE-158 (NCT026...

Acute Neurologic Complications of COVID-19 and Postacute Sequelae of COVID-19.
https://doi.org/10.1016/j.ccc.2022.03.002
Critical Care Clinics; Dangayach NS, Newcombe V et. al.

Jun 7th, 2022 - Neurologic complications can be seen in mild to severe COVID-19 with a higher risk in patients with severe COVID-19. These can occur as a direct consequence of viral infection or consequences of treatments. The spectrum ranges from non-life-threat...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  14 results

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome
https://clinicaltrials.gov/ct2/show/NCT05114941

Mar 16th, 2022 - Guillain-Barre syndrome (GBS) is an immune-mediated acute inflammatory peripheral neuropathy. The currently proven effective treatment methods include intravenous immunoglobulin and plasma exchange. In the clinical treatment process, the plasma so...

Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis
https://clinicaltrials.gov/ct2/show/NCT04057872

Feb 17th, 2022 - Background The incidence of sepsis has increased over the last four decades (1). Sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs. Severe sepsis and septic shock are amo...

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
https://clinicaltrials.gov/ct2/show/NCT04639024

Jan 25th, 2022 - This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation. ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug...

Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome
https://clinicaltrials.gov/ct2/show/NCT04053452

Jan 25th, 2022 - The purpose of this study is to determine if peripheral nerve ultrasound can be used as a supplemental tool to diagnose Guillain-Barre syndrome (GBS) in the acute setting and aid in prognostication.

Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome
https://clinicaltrials.gov/ct2/show/NCT04303962

Jan 19th, 2022 - Guillain-barre syndrome (GBS) is an acute immune-mediated polyneuropathy. Intravenous Gamma globulin is an effective therapy.Although high doses of gamma globulin are clinically effective, the patient's recovery and clinical prognosis vary. The es...

see more →

News  50 results

 Muscle-wasting Conditions May be More Common in the UK Than Previous Estimates
https://www.medscape.com/viewarticle/968599

Feb 16th, 2022 - Tens of thousands more people in the UK could be living with neuromuscular disease (NMD) than previous estimates suggested, according to new research. A study in the journal PLOS ONE, which analysed millions of GP records, suggested that the preva...

Slight Increase in Risk of Guillain-Barre After Recombinant Zoster Vaccine Confirmed
https://www.medscape.com/viewarticle/962005

Nov 2nd, 2021 - NEW YORK (Reuters Health) - An analysis of Medicare claims data found an increased risk of Guillain-Barre syndrome (GBS) following receipt of the recombinant zoster vaccine (RZV), confirming the same "signal" from the U.S. Centers for Disease Cont...

Safety Signal for Guillain-Barre With J&J COVID-19 Shot Confirmed in Surveillance Data
https://www.medscape.com/viewarticle/960777

Oct 14th, 2021 - NEW YORK (Reuters Health) - Data from the vaccine adverse event reporting system (VAERS) show a potential "small but statistically significant safety concern" for the development of Guillain-Barre syndrome (GBS) after receipt of the Janssen/Johnso...

The Delta Factor
https://www.mdedge.com/fedprac/article/246040/coronavirus-updates/delta-factor
Cynthia Geppert, MD, MA, MPH, MSBE

Sep 13th, 2021 - Several weeks ago, I received a call from my brother who, though not a health care professional, wanted me to know he thought the public was being too critical of scientists and physicians who “are giving us the best advice they can about COVID. P.

EU Lists Rare Nerve Disorder as Side Effect of J&J COVID-19 Vaccine
https://www.medscape.com/viewarticle/955233

Jul 23rd, 2021 - (Reuters) - Europe's medicines regulator said on Thursday it had added a nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson's COVID-19 vaccine after it reviewed 108 cases reported worldwide....

see more →

Patient Education  15 results see all →